najbardziej w życiu tęsknię za tym jak chodziłem z mamą do auchan na koniec wakacji na zakupy do szkoły po nowe zaszyty psiaczki kredki JAPIERDOLE JAK JA BYM NA TAKIE POSZEDŁ
@FATALASZKI997 Ja jeszcze żeby założyć te druty to musiałam zrobić zabieg recesji dziąsła za 4tys xDD myślałam że mnie pokurwi, o ósemkach nie wspomnę nawet
Let the countdown begin 🎤 BTS THE COMEBACK LIVE | ARIRANG. March 21 8pm KST / 4am PT. LIVE worldwide exclusively on Netflix.
#BTSLiveonNetflix#BTS_ARIRANG
Strasznie wczoraj zachlałem. Paliłem blanty do 5 rano. Film mi się urwał jak leżałem w rurze. Teraz mnie krzyż napierdala. Trochę się przespałem, ale musiałem wstać rano bo mam obowiązki. Mam pracę. Niektórzy mówią, że nie można chlać jak się ma pracę, ale…
Jungkook didn't go to sleep after the live but went to Itaewon, according to this girl on TikTok whose friend saw him there drunk after the live. Mind you, he had a group shooting schedule in a few hours.
Selfish, egoistic, immature man
This isn’t a random scientist who got lucky.
Mariano Barbacid discovered the first human oncogene in 1982. He isolated H-RAS from bladder cancer cells and proved a single point mutation could trigger cancer. That finding launched the entire field of molecular oncology.
KRAS mutations cause 90% of pancreatic cancers. For 43 years, oncologists called KRAS “undruggable” because the protein had no obvious binding pocket. Barbacid spent the last decade using genetically engineered mice to systematically test every node in the KRAS signaling pathway, looking for combinations that would work without killing the patient.
The triple therapy blocks KRAS three ways at once: the main growth signal, the escape routes through EGFR and HER2, and the stress-response backup through STAT3. Cut the engine, seal the exits, disable the emergency system. Tumors vanished in mice and didn’t return for 200+ days after treatment stopped.
Pancreatic cancer has a 13% five-year survival rate. 8% for the ductal adenocarcinoma type this therapy targets. Most patients live one year after diagnosis.
The catch: this is preclinical. Human trials are 3+ years away. One of the drugs, RMC-6236, might get approved this year, but the full triple combination has regulatory hurdles.
Still. The man who discovered human oncogenes in 1982 may have just figured out how to eliminate the cancer those genes cause. That’s a 43-year arc from first principles to potential cure. Science rarely works this clean.